EUCTR2020-003736-24-PL进行中（未招募）1 期
A Phase 3 International, Multicenter, Open-label Study to Evaluate the Safety and Immunogenicity of 9vHPV Vaccine Administered as 2-dose Regimen with Extended Dosing Intervals in 9- to 14-Year Old Boys and Girls Compared with a Standard 3- dose Regimen in 16- to 26-Year Old Women - Safety and Immunogenicity of Extended 2-dose Regimens of 9vHPV Vaccine
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 700
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Is healthy individual who meets all inclusion criteria and none of the exclusion defined in this section.
- •2. Is male or female, from 10 years to 15 years of age inclusive, who received 1 dose of 9vHPV vaccine at least 1 year prior to enrollment and did not receive Dose 2 of any HPV vaccine (Cohort 0).
- •3. Is male or female, from 9 years to 14 years of age inclusive, on the day of enrollment (Cohorts 1 to 4).
- •4. Is female, from 16 years to 26 years inclusive, on the day of enrollment (Cohort 5).
- •5. (Participants 9 to 15 years of age only) Has not yet had coitarche and does not plan on becoming sexually active during the vaccination period.
- •6. (Female participants 16 to 26 years of age only) Has never had Pap testing (cervical or anal) or has had only normal Pap test results.
- •7. (Female participants 16 to 26 years of age only) Has a lifetime history of 0 to 4 male and/or female sexual partners at the time of enrollment. Male or female partner is defined as someone with whom the participant has had penile penetrative sexual intercourse or someone who has contacted, either by penetrative (with fingers or other objects) or nonpenetrative means, the participant's genitalia during sexual activity.
- •8. (Female participants 16 to 26 years of age only, defined as WOCBP) Has not had sex with males or has had sex with males and used effective contraception with no failures since the first day of the participant’s last menstrual period through Day 1. The participant understands and agrees that during the intervention period, she should not have sexual intercourse with males without effective
- •contraception, and that the use of the rhythm method, withdrawal, and emergency contraception are not acceptable methods per the protocol. Effective contraception is defined as a marketed, approved contraceptive product that the participant has used per the manufacturer’s instructions with every act of sexual intercourse.
- •9. Participant or participant’s legally acceptable representative understands the study procedures, alternate treatments available, and risks involved with the study and voluntarily agrees to participate by providing documented informed consent. As appropriate based on local guidelines, the participant will also provide documented informed assent for the study. The participant or the participant’s legally acceptable representative may also provide assent/consent for future biomedical research. However, the participant may participate in the main study without participating in future biomedical research.
- •10. Agrees to provide study personnel with a primary telephone number as well as an alternate form of contact, if available, for follow-up purposes.
- •11. Participant or participant’s legally acceptable representative can read, understand, and complete the eVRC.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 90
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Has a fever (defined as oral temperature =100.0° F or =37.8° C) within the 24-hour period prior to the Day 1 visit.
- •2. Has a history of severe allergic reaction (eg, swelling of the mouth and throat, difficulty breathing, hypotension, or shock) that required medical intervention.
- •3. Is allergic to any vaccine component, including aluminum, yeast, or BENZONASETM (nuclease, Nycomed [used to remove residual nucleic acids from this and other vaccines]). For this exclusion criterion, an allergy to vaccine components is defined as an allergic reaction that met the criteria for severe AEs or SAEs.
- •4. Has known thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections.
- •5. Is currently immunocompromised or has been diagnosed as having congenital or acquired immunodeficiency, HIV infection, lymphoma, leukemia, systemic lupus erythematosus, rheumatoid arthritis, juvenile rheumatoid arthritis, inflammatory bowel disease, or other
- •autoimmune condition.
- •6. Has a history of splenectomy.
- •7. Is, at the time of signing informed consent, a user of recreational or illicit drugs or has
- •had a recent history (within the last year) of drug or alcohol abuse or dependence at the
- •discretion of the investigator. Alcohol abusers are defined as those who drink despite
- •recurrent social, interpersonal, and/or legal problems because of alcohol use.
- •8. Has a history of a positive test for HPV.
- •9. (Female participants 16 to 26 years of age only) Has a history of an abnormal cervical biopsy result (showing cervical intraepithelial neoplasia or worse).
- •10. (Female participants 16 to 26 years of age only) Has a history of HPV-related external genital lesions (eg, condyloma acuminata, or vulvar intraepithelial neoplasia) or external genital cancer, HPV-related vaginal lesions (eg, condyloma acuminata, or vaginal
- •intraepithelial neoplasia) or vaginal cancer, or HPV-related anal lesions (eg, condyloma acuminata, or anal intraepithelial neoplasia) or anal cancer.
- •11. (Female participants only) Is pregnant as determined by a serum pregnancy test or urine pregnancy test that is sensitive to 25 mIU/mL ß-hCG.
- •12. (Female participants only) Is expecting to donate eggs during the intervention period of the study.
- •13. Has a history or current evidence of any condition, therapy, lab abnormality or other circumstance that might confound the results of the study, or interfere with the participant’s participation for the full duration of the study, such that it is not in the best interest of the participant to participate by judgment of investigator.
- •14. Has received within 12 months prior to enrollment, is receiving, or plans to receive during the study, the following immunosuppressive therapies: radiation therapy, cyclophosphamide, azathioprine, methotrexate, any chemotherapy, cyclosporin,
- •leflunomide (AravaTM), TNF-a antagonists, monoclonal antibody therapies (including rituximab [Rituxan™]), IVIG, antilymphocyte sera, or other therapy known to interfere with the immune response. Regarding systemic corticosteroids, a participant will be excluded if he/she is currently receiving steroid therapy, has recently (defined as within 2 weeks of Day 1 vaccination) received such therapy, or has received 2 or more courses of corticosteroids lasting at least 1 week in duration in the year prior to Day 1 vaccination.
- •Participants using inhaled, nasal, or topical steroids are considered eligible for the study.
- •15. Has received within the 3 months prior to th
研究者
相似试验
进行中（未招募）
1 期
Safety and Immunogenicity of Extended 2-dose Regimens of 9vHPV VaccinePrevention of persistent anogenital HPV infection and disease caused by HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58MedDRA version: 21.1Level: PTClassification code: 10071146Term: Human papilloma virus immunisation Class: 100000004865CTIS2022-500256-37-00Merck Sharp & Dohme Corp.700
进行中（未招募）
不适用
Phase 3, multicenter, multi-national, open-label study to evaluate the safety and efficacy of alfimeprase in subjects with occluded central venous access devices (sonoma-3) - NDCentral venous access device withdrawal occlusionMedDRA version: 9.1Level: SOCClassification code 10042613Term: Surgical and medical proceduresEUCTR2006-000545-19-ITVELO800
进行中（未招募）
不适用
A multi-centre, multinational, phase 3, open-label extension trial to assess the safety of long-term treatment of rotigotine patch in subjects with advanced stage, idiopathic Parkinson's disease who are not well controlled on levodopa - N/AParkinson's DiseaseEUCTR2004-000148-26-FISchwarz BioSciences Inc.360
进行中（未招募）
1 期
A multi-centre, multinational, phase 3, open-label extension trial to assess the safety of long-term treatment of rotigotine patch in subjects with advanced stage, idiopathic Parkinson's disease who are not well controlled on levodopa - N/AParkinson's DiseaseEUCTR2004-000148-26-ESSchwarz BioSciences Inc.360
进行中（未招募）
不适用
A multi-centre, multinational, phase 3, open-label extension trial to assess the safety of long-term treatment of rotigotine patch in subjects with advanced stage, idiopathic Parkinson's disease who are not well controlled on levodopa - N/AParkinson's DiseaseEUCTR2004-000148-26-SESchwarz BioSciences Inc.360